3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Cholangiocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Papillomavirus Infections
1
Oncogenic osteomalacia
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Hypophosphatemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Acrocephalosyndactylia
1
Interventions
Ipilimumab
106
Nivolumab
101
pembrolizumab
90
aldesleukin
72
Cyclophosphamide
46
Interleukin-2
45
Temozolomide
36
Dacarbazine
32
trametinib
31
dabrafenib
30
fludarabine phosphate
29
incomplete Freund's adjuvant
27
Bevacizumab
26
sargramostim
25
Vemurafenib
25
fludarabine
22
binimetinib
21
Radiosurgery
21
Paclitaxel
20
encorafenib
19
Carboplatin
19
CTLA-4 Antigen
18
cobimetinib
16
atezolizumab
15
Radiotherapy
14
Biopsy
14
Sorafenib
13
MART-1 Antigen
12
talimogene laherparepvec
11
montanide ISA 51
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Melanoma
×
infigratinib
×
Clear all
NCT02159066
2024-03-05
LOGIC-2
Pfizer
Phase 2
Completed
158 enrolled
40 charts